Open Access. Powered by Scholars. Published by Universities.®

Medicinal-Pharmaceutical Chemistry Commons

Open Access. Powered by Scholars. Published by Universities.®

Diseases

University of Massachusetts Medical School

AIDS

Articles 1 - 1 of 1

Full-Text Articles in Medicinal-Pharmaceutical Chemistry

A Novel Bromodomain And Extra-Terminal Domain Inhibitors (Beti) That Reverses Hiv-1 Latency, Shuai Liu, Maxime Jean, Wei Zhang, Jian Zhu May 2017

A Novel Bromodomain And Extra-Terminal Domain Inhibitors (Beti) That Reverses Hiv-1 Latency, Shuai Liu, Maxime Jean, Wei Zhang, Jian Zhu

UMass Center for Clinical and Translational Science Research Retreat

Although combinatory antiretroviral therapy (cART) is effective to reduce HIV-1 viremia, it does not eliminate HIV-1 infection. HIV-1 remains latent with the presence of cART, impeding the cure of AIDS. Recently, latency-reversing agents (LRAs) have been developed to purge latent HIV-1, providing an intriguing strategy for eradication of residual, latent viral reservoirs. Our earlier studies show that antagonism of HIV-1 competitive factor bromodomain containing 4 (BRD4) using bromodomain and extra-terminal domain inhibitor (BETi) JQ1 may facilitate the reversal of HIV-1 latency. BETis have recently emerged as a class of compounds that are promising for both the anticancer and HIV-1 latency-reversing ...